CSIMarket Company Name, Ticker, Customers, else..
 
Biolase Inc   (BIOL)
Other Ticker:  
 
 
Price: $0.0174 $-0.04 -71.981%
Day's High: $0.056 Week Perf: -72.77 %
Day's Low: $ 0.02 30 Day Perf: -67.17 %
Volume (M): 4,599 52 Wk High: $ 1.05
Volume (M$): $ 80 52 Wk Avg: $0.18
Open: $0.04 52 Wk Low: $0.02



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 36
 Employees 250
 Revenues (TTM) (Millions $) 44
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Biolase Inc
Biolase Inc is a medical device company that specializes in the development and commercialization of dental lasers. The company was founded in 1987 and is headquartered in Irvine, California. Biolase's flagship product is Waterlase, a dental laser that uses a combination of laser energy and water to perform a range of dental procedures with less pain and faster healing times than traditional methods. In addition to Waterlase, the company also offers other laser-based products for dental and medical applications. Biolase has a global presence and sells its products in over 90 countries worldwide.


   Company Address: 27042 Towne Centre Drive Lake Forest 92610 CA
   Company Phone Number: 361-1200   Stock Exchange / Ticker: BIOL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALGN        4.94% 
HSIC        3.56% 
MDT        7.69% 
OMI        0.07% 
SYK        6.22% 
ZBH        3.86% 
• View Complete Report
   



Stock Offering

BIOLASE Announces $1.4 Million Securities Purchase Agreement, Impacts Shareholders and Reflects a Bullish Future

Published Wed, Dec 6 2023 6:46 PM UTC



LAKE FOREST, Calif., Dec. 6, 2023 - BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, has recently unveiled a major development for the company and its shareholders. This press release reveals that BIOLASE has entered into a securities purchase agreement with a single institutional investor to acquire approximately $1.4 million of its common stocks....
Biolase Inc

Biolase Inc Struggles with Steep -10.525% Revenue Decrease amid Challenging Business Environment

Biolase Inc is a medical device company that specializes in the development and manufacturing of dental lasers. The company has been in operation for several years and has experienced some ups and downs in its financial performance.
For the fiscal third quarter of 2023, Biolase Inc reported a widened deficit of $-3.89 per share compared to $-1.10 per share in the same period the previous year. However, there was some improvement in the EPS, which increased from $-8.93 per share in the prior financial reporting period.
The revenue for the quarter declined by -10.525% to $10.75 million from $12.01 million in the corresponding period a year prior. Sequentially, the revenue fell by -23.884% from $14.12 million. This decline in revenue may be a cause for concern for the company, as it suggests a slowing demand for its products.
Biolase Inc

Biolase Inc Achieves Unprecedented Growth with Ease in the Latest Fiscal Period

Financial News Report: Biolase Inc Reports Increase in Deficit per Share and Impressive Revenue Growth
Biolase Inc, a leading Medical Equipment & Supplies company, recently released its financial results for the fiscal span ending June 30, 2023. The company reported an increase in deficit per share, but also witnessed significant revenue growth.
During the fiscal span ending June 30, 2023, Biolase Inc reported a deficit per share of $-8.93, compared to $-0.91 in the previous year. This represents a surge in deficit from the preceding reporting period, where the deficit per share stood at $-0.18. Despite the increased deficit, the company reported a substantial increase in revenue. Revenue inched up by 15.39% to $14.12 million from $12.24 million in the corresponding reporting period a year before. Moreover, sequentially, revenue surged by 34.881% from $10.47 million.
Biolase Inc reported a net deficit of $-4.868 million for the fiscal span ending June 30, 2023, compared to a deficit of $-5.611 million in the corresponding reporting period a year ago. These results highlight the company's ongoing challenge in reducing its deficit and improving profitability.
Biolase Inc

Biolase Inc Struggles with Negative ROI and Record Losses in Recent Fiscal Year2.

Biolase Inc, a global leader in dental lasers, has been facing significant financial challenges as evidenced by its negative return on investment (ROI) of -108.69% in the fiscal year ending March 31, 2023. The company recorded a cumulative net loss of $-30 million during the 12-month period, which is a significant decline compared to the previous year. According to reports, within the healthcare sector, 625 other companies had a higher return on investment than Biolase.
Despite these financial challenges, the company has witnessed an improvement in its overall ranking in the ROI from the fourth quarter of 2022 when it ranked at position 4501 to position 3269 in the first quarter of 2023. This improvement is a bright spot for the company as it indicates that there may be a reversal of fortunes in the pipeline.






Biolase Inc's Segments
United States    79.43 % of total Revenue
International    25.08 % of total Revenue
Revenue Recognized Over Time    12.11 % of total Revenue
Revenue Recognized at a Point in Time    92.4 % of total Revenue
End-customer    79.43 % of total Revenue
Distributors    25.08 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com